Mediab S.R.L. — Clinical Trial Site

21 Registered trials

7 Currently recruiting

Organisation

Mediab S.R.L.

Location

Targu Mures, Romania

Identifier

ORG-100042776

Address

Apartament I-II, Strada Marinescu Gheorghe Nr 8a, 540142, Romania

Departments

#3207: Cardiology
Cardiology
Diabet
Diabet zaharat, Nutritie si Boli metabolice
Diabetes
Diabetes-Nutrition-Metabolic Disorders
Diabetes, Nutrition and Metabolic disease
Diabetes, Nutrition and Metabolic Disease Department
Diabetes, Nutrition and Metabolic Diseases
Diabetology
Private Practice, Diabetes and Cardiology
Psihiatrie
Psychiatry
Specialitatea–Diabet zaharat, nutritie si boli

Clinical trials at this site (21)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Type 2 Diabetes 5 2024-10-18
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Type 2 Diabetes 4 2024-07-26
A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight (TRIUMPH-2) Ended

2023-503658-11-00 Type 2 Diabetes 5 2023-08-31
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5